Collaborative effort to optimize conditions for large-scale stem cell cultivation.
Billerica, Mass. -- based EMD Millipore, a division of Merck KGaA, and the Centre for Commercialization of Regenerative Medicine (CCRM) said they would collaborate on development of optimized conditions for bioreactor-based cultivation of stem cells.
This joint project will focus on the development of a proprietary monitoring and control methodology, enabling robust growth of adherent human pluripotent stem cells in EMD Millipore's Mobius CellReady stirred tank bioreactor. Ultimately, the project will deliver a commercially available kit containing reagents and associated methodologies for bioreactor culture of stem cells on microcarriers.
"As the demand for stem cells used in drug discovery and clinical applications grows, effectively translating the promise of stem cells into therapeutic reality will require large-scale, industrialized production under tightly controlled conditions," said Robert Shaw of EMD Millipore. "At this time, production is typically achieved using stacks of 2D tissue culture vessels, which is an expensive and labor intensive process. This joint project will address those challenges and facilitate optimized, large-scale cultivation of stem cells which can accelerate the progress of therapies into the clinic."
CCRM will be employing EMD Millipore's Mobius CellReady stirred tank bioreactor in its product development facility at the University of Toronto's Banting Institute.
The work began on February 27, 2012.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Advanced Stem Cell Technology|
|Publication:||Stem Cell Lab World|
|Date:||Mar 12, 2012|
|Previous Article:||MaxCyte to discuss gram-scale antibody and protein production at conference.|
|Next Article:||New screening method rapidly identifies key stem cell information.|